Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
R131 vaginal ointment for HPV-associated cervical intraepithelial neoplasia
ACTRN12618001726246Phase 2Terminated
- Sponsor
- Douglas Pharmaceuticals
- Start
- Apr 2019
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label trial of interferon alfa-2b in cervical intraepithelial neoplasia (CIN) and human papillomavirus infection, sponsored by Douglas Pharmaceuticals. Started Apr 2019; status: terminated.
02
Drugs
interferon alfa-2b
03
Conditions
cervical intraepithelial neoplasia (CIN)human papillomavirus infection
Beyond the preview
Go deeper on ACTRN12618001726246.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12618001726246.